New drug combo shows promise in shrinking head and neck tumors before surgery
NCT ID NCT04848116
First seen Jan 09, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This study tests whether giving two drugs—nivolumab and BMS-986253—before surgery can safely shrink tumors in people with head and neck cancer. About 24 adults with HPV-negative squamous cell carcinoma will receive the combination before their planned surgery. The main goals are to check safety and see if the treatment helps reduce the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.